OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

The efficacy and safety of the anti–programmed death ligand 1 ( PD-L1 ) monoclonal antibody Atezolizumab ( Tecentriq ), as compared with those of Platinum-based chemotherapy, as first-line treatment ...


Five-year survival results from the pivotal phase 3 KEYNOTE-024 trial were presented at ESMO Virtual Congress 2020. Sustained, long-term survival benefit and durable responses with Pembrolizumab ( ...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib ( Xalkori ) in treatment-naive ALK-positive non-small-cell lung c ...


According to phase II trial PRINCEPS, no safety signals were raised, no major toxicity and no surgery impairment were reported following one cycle of neoadjuvant Atezolizumab ( Tecentriq ) therapy in ...


Entrectinib ( Rozlytrek ) is a potent, selective, CNS active, ROS1 tyrosine kinase inhibitor ( TKI ). In a preliminary analysis ( data cut-off: 31 May 2018 ) of patients with ROS1 fusion-positive ( ...


Pembrolizumab ( Keytruda ) plus Olaparib ( Lynparza ) has shown antitumor activity and acceptable safety in Docetaxel-pretreated pts with metastatic castration-resistant prostate cancer ( mCRPC ) enro ...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake research to identify biomarkers of response and resis ...


Ibrutinib ( Imbruvica ), a once-daily Bruton’s tyrosine kinase ( BTK ) inhibitor approved for various B-cell malignancies, also inhibits other kinases, such as ITK and ETK ( Wang Clin Cancer Res 2018 ...


Preclinical evidence has suggested that Niraparib ( Zejula ), a poly (ADP-ribose) polymerase inhibitor, may synergise with PD-1 inhibitors. Pembrolizumab ( Keytruda ) is a PD-1 inhibitor approved a ...


MET exon 14 skipping mutations ( METex14 ) are seen in 3-4% of patients with non-small cell lung cancer ( METex14 NSCLC ) and are associated with poor outcomes. In the phase 2 GEOMETRY mono-1 stud ...


The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer ( nmCRPC ) who had prostate-specific antigen doubling time ...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small cell lung cancer ( NSCLC ) and high programmed death-ligand ...


Non-clear cell renal cell carcinoma ( nccRCC ) encompasses a heterogenous group of histologies comprising approximately 25% of all renal cell carcinoma ( RCC ) diagnoses with worse outcomes than clear ...


Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum testosterone at castrate levels. The absence of metastases ( M0 ...


Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of adjuvant therapy with Dabrafenib ( Tafinlar ) plus Trametinib ( Mekinis ...